Regeneron Pharmaceuticals (REGN) shares tanked this morning as the biotech firm announced its highly anticipated Phase 3 trial evaluating an experimental skin cancer combination therapy failed to meet its primary endpoint.
The late-stage trial REGN’s fianlimab (LAG-3 inhibitor), combined with its established immuno-therapy Libtayo, against Merck’s (MRK) blockbuster standard-of-care, Keytruda, in over 1,500 advanced melanoma patients.